EMA committee recommends Yuviwel (navepegritide) for children with achondroplasia

Šis įrašas rodomas anglų kalba, kol bus atnaujintas jo vertimas.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended authorising Yuviwel (navepegritide), a prodrug containing C-type natriuretic peptide, for children aged 2 years and older with genetically confirmed achondroplasia whose epiphyses (bone growth plates) are not closed. In a 52-week randomised, double-blind, placebo-controlled trial, it improved annualised growth velocity by 1.49 cm compared with placebo. The most common side effects were injection site reactions and hypertrichosis (abnormal hair growth). A CHMP opinion is followed by a European Commission decision.

Šaltiniai

  1. 01Yuviwel: opinion on marketing authorisation(šaltinis atsidaro naujame skirtuke) European Medicines Agency
  2. 02Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026(šaltinis atsidaro naujame skirtuke) European Medicines Agency